News Galapagos drops plan to split after 'market developments' Shortly after announcing a plan to separate its drug and cell therapy businesses into two separate companies, Galapagos has had a change of heart.
News Galapagos unveils plan to split, hiving off its drugs unit Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its drug development and cell therapy operations.
News Paul Stoffels swiftly resurfaces as Galapagos' next CEO Paul Stoffels' retirement at the end of last year after nine years as head of R&D at Johnson & Johnson was short lived – he's just been named chef executive of Galapagos.
News J&J's long-serving R&D chief Paul Stoffels announces retirem... Paul Stoffels is bringing a nine-year tenure as head of R&D at Johnson & Johnson to a close, announcing plans to retire at the end of the year.
News Iambic prices its IPO, seeking to raise up to $160m AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.